Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC -0.11%74 Debt-to-Equity is 3.65 as of Mar. 2026, which is 13% below its 10-year median of 4.18. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.37 (Fairly Valued). The stock has 3 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 96.72% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sotera Health Co's Debt-to-Equity or its related term are showing as below:
SHC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.51 Med: 4.18 Max: 50.45
Current: 3.65
During the past 8 years, the highest Debt-to-Equity Ratio of Sotera Health Co was 50.45. The lowest was -4.51. And the median was 4.18.
SHC's Debt-to-Equity is ranked worse than 96.72% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs SHC: 3.65
Sotera Health Co (NAS:SHC) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sotera Health Co Debt-to-Equity Related Terms
Sotera Health Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs VCYT, RDNT, BLLN: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co (SHC) has a Debt-to-Equity of 3.65 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sotera Health Co and its competitors. This is 13% below median its historical median of 4.18. According to the industry distribution chart, Sotera Health Co ranks #177 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 96.7%.
Is Sotera Health Co's Debt-to-Equity too high?
Sotera Health Co's current Debt-to-Equity of 3.65 is 13% below median its 10-year median of 4.18. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Sotera Health Co's value of 3.65 is 1006.1% above this industry median. Based on the distribution chart, Sotera Health Co ranks #177 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Debt-to-Equity compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #177 out of 183 companies for Debt-to-Equity. This places Sotera Health Co in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Sotera Health Co's value of 3.65 is 1006.1% above this benchmark. While the company's 10-year median is 4.18 vs. the industry median of 0.33, Sotera Health Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current Debt-to-Equity of 3.65 is 1006.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current Debt-to-Equity is 3.65, which is 13% below median its own 10-year median of 4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.37, compared to a current price of $17.40 — trading 6.3% above its estimated fair value. The current Debt-to-Equity is 3.65, which is 13% below median its 10-year median of 4.18 and 1006.1% above the Medical Diagnostics & Research industry median of 0.33. Sotera Health Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Debt-to-Equity is 3.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.40 is trading 6.3% above its estimated GF Value™ of $16.37.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
Debt-to-Equity: 3.65 (13% below median its 10-year median of 4.18)
GF Value™: $16.37 vs. price of $17.40 (6.3% above fair value)
Industry Position: 1006.1% above the Medical Diagnostics & Research median (#177 of 183)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
